September 14, 2018 2017 was another record year for medical biotechnology in Germany

The latest biotech report from vfa bio and the Boston Consulting Group on the state of medical biotechnology in Germany is now available

In his interview, Dr. Frank Mathias, CEO of Rentschler Biopharma SE and Chairman of vfa bio, summarizes the most important findings and developments.

In 2017, sales of biopharmaceuticals in Germany developed very positively, leading to a 10% year-on-year increase to 10.2 billion euros. This growth is also the reason for a rise in the market share of biopharmaceuticals in the entire pharmaceutical market. One of the main reasons for this growth is the increasing demand for biopharmaceutical drugs.

Have a look at the following video that summarizes the most important key figures of medical biotechnology in Germany: